Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

comunicati

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

26.03.2020 - 07:45

0

SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis

Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe

SEATTLE and BRISBANE, Australia, March 26, 2020 /PRNewswire/ -- Immunexpress, Inc. a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced it has received CE Marking of SeptiCyte® RAPID for its host response technology. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla™ platform, providing actionable results in about one hour to guide the physician to optimize patient management decisions.

The CE Marking of SeptiCyte® RAPID is a significant accomplishment for Immunexpress, enabling the company to market and sell the near-patient sample-to-answer test in European Union (EU) member countries and those  harmonized with the EU IVD Directive (98/79/EC). Immunexpress plans to immediately initiate commercial operations in Europe, and announced a long-term commercialization partnership with Biocartis NV, an industry leader in the molecular diagnostic space. Biocartis currently has over 1,300 Idylla™ instruments installed throughout the world.  

"Achieving the CE IVD registration and entering commercialization of Immunexpress' leading host response SeptiCyte technology represents a new and exciting phase for our company," said Rolland Carlson, Ph.D., Chief Executive Officer of Immunexpress. "We believe Biocartis, with its well established and growing customer base, will be highly effective in delivering to the European community a new and novel sepsis diagnostic tool, designed to enhance the certainty of early and rapid sepsis diagnosis, to improve clinical outcomes and to lower healthcare costs."

The ongoing COVID-19 pandemic underscores the unmet need for technologies that efficiently discriminate patients with mild infection from those that may develop serious complications related to sepsis, especially when critical medical resources are in short supply. In a recent study of the risk factors associated with COVID-19 mortality, sepsis was the most frequently observed complication1. The early diagnosis of bacterial and viral sepsis with SeptiCyte® RAPID, including the immediate and overwhelming global need to triage COVID-19 patients with worsening prognoses, will ensure rapid initiation of sepsis management protocols increasing the potential to save lives.

Dr. Carlson continued, "Together with Biocartis, Immunexpress is committed to mitigating the constraints on hospitals that are affected by the COVID-19 pandemic. We are urgently working towards improving patient outcomes by swiftly triaging COVID-19 patients to receive the most appropriate treatment. Accurate diagnostic testing of sepsis is more important now than ever to enable physicians to make rapid clinical decisions in resource-constrained ICUs."

About SeptiCyte® RAPID

SeptiCyte® RAPID is a gene expression assay using reverse transcription polymerase chain reaction (PCR) to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene® Blood RNA Tube. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis. SeptiCyte® RAPID generates a score (SeptiScore™) that falls within one of three discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. SeptiCyte® RAPID is intended for in-vitro diagnostic use and is used on the Biocartis Idylla™ System.

About BiocartisBiocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

About ImmunexpressImmunexpress is a molecular diagnostic company, founded in Australian and based out of Seattle, Washington, USA, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's immune response by quantifying and analyzing gene expression signatures from whole blood, providing actionable results in about an hour to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis' Idylla™ platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis. This powerful combination of technologies enhances certainty for early sepsis diagnosis, to improve clinical outcomes and lower healthcare costs. For more information visit http://www.immunexpress.com/.

Follow Immunexpress on Twitter and LinkedIn.

*Immunexpress is licensed to use the Idylla™ trademark from Biocartis NV.

Media Contacts: Maggie BellerRusso Partners, LLC+1(646) 942-5631Maggie.beller@russopartnersllc.com

1Zhou, F., et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

Logo - https://mma.prnewswire.com/media/1033289/Immunexpress_Inc.jpg   

Condividi le tue opinioni su Corriere dell'Umbria

Caratteri rimanenti: 400

Più letti oggi

Mediagallery

Sirene spiegate e applausi, l'omaggio dei vigili del fuoco agli operatori sanitari a New York

Sirene spiegate e applausi, l'omaggio dei vigili del fuoco agli operatori sanitari a New York

(Agenzia Vista) New York, 04 aprile 2020 Sirene spiegate e applausi, l'omaggio dei vigili del fuoco agli operatori sanitari a New York I vigili del fuoco di New York hanno reso omaggio agli operatori sanitari in prima linea per combattere l'emergenza coronavirus, fermandosi con le sirene spiegate ad applaudire fuori dagli ospedali. Fonte: Twitter Fonte: Agenzia Vista / Alexander Jakhnagiev

 
Coronavirus, Tremonti: "Eurobond sarebbero stati soluzione maestra"

Coronavirus, Tremonti: "Eurobond sarebbero stati soluzione maestra"

(Agenzia Vista) Roma, 04 aprile 2020 Coronavirus, Tremonti: "Eurobond sarebbero stati soluzione maestra" La videovconfereza di Europa Etica dei cittadini e delle autonomie, con la partecipazione di Giulio Tremonti, del presidente di Federterziario, Nicola Patrizi, del presidente dell'associazione Guido Carli, Federico Carli e con Angelo Polimeno Bottai, presidente di Eureca e vicedirettore del ...

 
Video Elettra Lamborghini, piccolo paziente e due infermiere ballano all'ospedale Musica (e il resto scompare)
Social

Video Elettra Lamborghini, piccolo paziente e infermiere ballano in corsia

"Il video più bello che vedrai oggi". Esulta Elettra Lamborghini nel pubblicare un filmato sul suo profilo Instagram. E ha ragione. Si tratta di immagini molto particolari, soprattutto in piena quarantena da Coronavirus. Mostrano, infatti, un piccolo paziente dell'Ospedale Pausilipon di Napoli mentre balla in corsia insieme a due infermiere, sulle note del brano Musica (e il resto scompare), ...

 
De Luca: "A Pasqua state a casa e fate la pastiera anche se sarà una sozzeria"

De Luca: "A Pasqua state a casa e fate la pastiera anche se sarà una sozzeria"

(Agenzia Vista) Napoli, 04 aprile 2020 De Luca: "A Pasqua state a casa e fate la pastiera anche se sarà una sozzeria" "A Pasqua non rilassiamoci, e’ un periodo delicato, rimanete a casa, magari imparate a fare pranzi e dolci. Fate le pastiere. Non dico di mangiarle, almeno le prime saranno una sozzeria, ma dopo i primi esperimenti impareremo. L’importante è che rimaniate in casa”. Così il ...

 
Vasco Rossi e la musica: "Così facciamo urlare le idee. Arrivano al cuore"

Social

Vasco Rossi e la musica: "Così facciamo urlare le idee. Arrivano al cuore"

La forza nella musica. Anche e soprattutto in tempo di Coronavirus. Vasco Rossi, attivissimo sui social negli ultimi tempi, esalta con un post sui suoi profili l'importanza ...

04.04.2020

Video Elettra Lamborghini, piccolo paziente e due infermiere ballano all'ospedale Musica (e il resto scompare)

Social

Video Elettra Lamborghini, piccolo paziente e infermiere ballano in corsia

"Il video più bello che vedrai oggi". Esulta Elettra Lamborghini nel pubblicare un filmato sul suo profilo Instagram. E ha ragione. Si tratta di immagini molto particolari, ...

04.04.2020

Un posto al sole si ferma a causa del Coronavirus, dal 6 aprile le repliche della sedicesima stagione

Televisione

Un posto al sole si ferma a causa del Coronavirus, dal 6 aprile le repliche della sedicesima stagione

Un posto al sole si ferma a causa del Coronavirus. La popolare soap opera da lunedì 6 aprile 2020 andrà in onda riproponendo gli episodi della sedicesima stagione, girata a ...

04.04.2020